Effect of CEP-751 treatment on prostate cancer volume, proliferation, and death rate
| Tumor type | host | Treatment (time) | Cancer volumea | Percentage of Cancer Cells | ||
|---|---|---|---|---|---|---|
| Proliferation day | Dying day | |||||
| AT-2 | Rats | Vehicle (10 days) | 15.2 ± 1.1 | 49.3 ± 3.2 | 24.5 ± 1.8 | |
| CEP-751b (10 days) | 6.1 ± 0.5c | 57.6 ± 1.4 | 37.2 ± 4.1c | |||
| LNCaP | Nude mice | Vehicle (21 days) | 4.2 ± 0.3 | 23.4 ± 5.1 | 14.0 ± 2.1 | |
| CEP-751b (21 days) | 1.7 ± 0.2c | 25.2 ± 6.3 | 21.8 ± 2.5c | |||
a Cancer volume expressed as fold increase from initiation of treatment.
b CEP-751 given s.c. at 10 mg/kg/dose. For AT-2, rats were given one dose/day; for LNCaP and TSU-pr1, nude mice were given two doses/day.
c P < 0.01 versus vehicle control.